LogicBio Therapeutics (LOGC) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
EPS Growth %: +42.9%
Financial Fact:
Sales, general and administrative: 167.9K
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +42.9%
Financial Fact:
Sales, general and administrative: 167.9K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q3 EPS of ($0.04).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loews Corp. (L) Reports Q3 EPS of $1.50
- Lumentum (LITE) PT Lowered to $1,132 at Mizuho
- Upwork Inc. (UPWK) call put ratio 1 call to 1 put a share price up 8.3%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
